Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 7/20 | 0.62 |
| ▸ | GRIK2 | Q13002 | 7/20 | 0.62 |
| ▸ | CPA1 | P15085 | 2/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | LAP3 | P28838 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885655 | 1.00 | GRIK1 (0.62) | GRIK1GRIK2CPA1SLC1A3SLC1A2 | |
| SCHEMBL7305997 | 1.00 | GRIK1 (0.62) | GRIK1GRIK2CPA1SLC1A3SLC1A2 | |
| SCHEMBL6050002 | 0.89 | GRIK1 (0.75) | GRIK1GRIK2CPA1SLC1A3SLC1A2 | |
| SCHEMBL7600008 | 0.82 | GRIK1 (0.56) | GRIK1GRIK2CPA1SLC1A3SLC1A2 | |
| SCHEMBL891727 | 0.81 | GRIK1 (0.64) | GRIK1GRIK2CPA1CYP2C19 | |
| SCHEMBL19483375 | 0.81 | GRIK1 (0.41) | GRIK1GRIK2CPA1SLC1A3SLC1A2 | |
| SCHEMBL19483400 | 0.81 | GRIK1 (0.41) | GRIK1GRIK2CPA1SLC1A3SLC1A2 | |
| SCHEMBL5849604 | 0.81 | GRIK1 (0.50) | GRIK1GRIK2CPA1SLC1A3SLC1A2 | |
| SCHEMBL526016 | 0.80 | SLC1A3 (0.52) | GRIK1GRIK2CPA1SLC1A3SLC1A2 | |
| SCHEMBL3111378 | 0.79 | SLC1A3 (0.47) | GRIK1GRIK2CPA1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388007-B2 | Gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-7338974-B2 | Macrocyclic diaminopropanes as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338974-B2 | Macrocyclic diaminopropanes as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338974-B2 | Macrocyclic diaminopropanes as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| WO-2007021793-A1 | MACROCYCLIC DIAMINOPROPANES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021793-A1 | MACROCYCLIC DIAMINOPROPANES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-15 | — | — | US | disclosed |
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-15 | — | — | US | disclosed |
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-15 | — | — | US | disclosed |
| WO-2006026204-A2 | NOVEL GAMMA-LACTAMS AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060046984-A1 | Novel gamma-lactams as beta-secretase inhibitors | THOMPSON LORIN A III | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046984-A1 | Novel gamma-lactams as beta-secretase inhibitors | BACE1, BACE2, APP | GRIK1 348/4885GRIK2 629/4885CPA1 1213/4885 |
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | APP, BACE1, PSEN1 | GRIK1 1962/4885GRIK2 1549/4885CPA1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.